	US 11,932,671 B2
	Modified meningococcal fHbp polypeptides
Matthew Bottomley, Siena (IT); Enrico Malito, Siena (IT); Manuele Martinelli, Siena (IT); and Maria Scarselli, Siena (IT)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Apr. 30, 2021, as Appl. No. 17/245,681.
Application 17/245,681 is a division of application No. 16/458,365, filed on Jul. 1, 2019, granted, now 11,021,522.
Application 16/458,365 is a division of application No. 15/120,674, granted, now 10,392,424, issued on Aug. 27, 2019, previously published as PCT/EP2015/054174, filed on Feb. 27, 2015.
Claims priority of application No. 14157399 (EP), filed on Feb. 28, 2014; and application No. 14177566 (EP), filed on Jul. 17, 2014.
Prior Publication US 2021/0253647 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 37/04 (2006.01); A61K 39/095 (2006.01); C07K 14/22 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/22 (2013.01) [A61K 39/095 (2013.01); A61K 2039/523 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/70 (2013.01)]

11 Claims

1. A fusion polypeptide comprising a mutant v2 fHbp polypeptide and/or a mutant v3 fHbp polypeptide and at least one other fHbp, wherein:

i. the mutant v2 fHbp polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 5 and includes a residue corresponding to residue 32 from SEQ ID NO: 5, wherein the amino acid sequence of the mutant v2 fHbp polypeptide differs from SEQ ID NO: 5 at residue 32 by the substitution S32V; and/or

ii. the mutant v3 fHbp polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 17 and includes a residue corresponding to residue 32 from SEQ ID NO: 17, wherein the amino acid sequence of the mutant v3 fHbp polypeptide differs from SEQ ID NO: 17 at residue 32 by the substitution S32V.